Clinical and Experimental Research in Parkinson’s Disease and Other Neurodegenerative Movement Disorders
Molecular pathophysiological mechanisms including genetics and epigenetics, biomarkers, both biochemical (chiefly CSF) and imaging and experimental therapies (clinical trials) in Parkinson’s disease and other movement disorders.
Principal Investigators
Yaroslau Compta
Neurologist
Technologies & Methods
- Disease/disorder characterisation: Endophenotypification studies
- Assessment of new treatments: Clinical trials, non-dopa agents
- Methods for diagnostic: Cerebrospinal fluid (CSF) and imaging biomarkers
- Clinical data: Collaborative clinical registries
- Development of new tools / technologies / computational methods: Implement new CSF (RTQuIC) and PET (foreseeably in the future tau and eventually alpha-synuclein) markers
Research Team
Esteban Muñoz
Adjunct medical professor
Francesc Valldeoriola
Adjunct medical professor
Lorena de Mena
Postdoctoral Researcher
Almudena Sánchez
Postdoctoral Researcher
Alexandra Perez-Soriano
Postdoctoral Researcher
Celia Painous
Postdoctoral Researcher
Alicia Garrido
Postdoctoral Trainee
Carla Brenlla
Early Stage Researcher
Ana Camara
Early Stage Researcher
Ona Brengaret
Early Stage Researcher
Carlos Lázaro
Early Stage Researcher
Manel Fernandez
Technician
Jessica Pérez Montesino
Technician
Alejandro Rubiano
Technician
Guillem Pares
Technician
Carlos A Bambaren
Technician
Active Projects
Plataforma Traslacional para la AMS: Descubriendo mecanismos patológicos y nuevas dianas terapéuticas: PTra-ADPT
Instituto de Salud Carlos III. AC21_2/00018. Yaroslau Compta.
PSP REGISTRY: CLINICAL COHORT STUDY WITH BIOMARKERS STUDY OF PREDIAGNOSTIC CASES AND HEALTH EDUCATION PROGRAM IN ESTABLISHED DISEASE.
Fundació La Marató de TV3. 202009-10. Yaroslau Compta.
Selected publications
Alvarez-Mora, M. I., Rodríguez-Revenga, L., Jodar, M., Potrony, M., Sanchez, A., Badenas, C., Oriola, J., Villanueva-Cañas, J. L., Muñoz, E., Valldeoriola, F., Cámara, A., Compta, Y., Carreño, M., Martí, M. J., Sánchez-Valle, R., & Madrigal, I. (2023). Implementation of Exome Sequencing in Clinical Practice for Neurological Disorders. Genes, 14(4), 813. https://doi.org/10.3390/genes14040813
Buongiorno, M., Marzal, C., Fernandez, M., Cullell, N., de Mena, L., Sánchez-Benavides, G., de la Sierra, A., Krupinski, J., & Compta, Y. (2023). Altered sleep and neurovascular dysfunction in alpha-synucleinopathies: the perfect storm for glymphatic failure. Frontiers in Aging Neuroscience, 15. https://doi.org/10.3389/fnagi.2023.1251755
Carrasco, M., Camara, A., & Compta, Y. (2023). Healthy diet versus added sugars and unsaturated fatty acids in Parkinson’s disease: Food for thought. Parkinsonism & Related Disorders, 115, 105865. https://doi.org/10.1016/j.parkreldis.2023.105865
Martínez, M., Ariz, M., Alvarez, I., Castellanos, G., Aguilar, M., Hernández-Vara, J., Caballol, N., Garrido, A., Bayés, À., Vilas, D., Marti, M. J., Pascual-Sedano, B., Marin, J., Avila, A., Buongiorno, M., Tartari, J. P., Puente, V., Ezquerra, M., Valldeoriola, F., … Pastor, M. A. (2023). Brainstem neuromelanin and iron MRI reveals a precise signature for idiopathic and LRRK2 Parkinson’s disease. Npj Parkinson’s Disease, 9(1), 62. https://doi.org/10.1038/s41531-023-00503-2
Painous, C., & Compta, Y. (2023). Sacades, pupils and blink tracking: More than meets the eye in the Parkinson’s disease cognitive spectrum? Parkinsonism & Related Disorders, 110, 105363. https://doi.org/10.1016/j.parkreldis.2023.105363
Parnetti, L., Bellomo, G., & Compta, Y. (2023). Lipoproteins and α-synuclein in cerebrospinal fluid in Parkinson’s disease: “Dangerous liaisons” on the road to neurodegeneration? Parkinsonism & Related Disorders, 116, 105884. https://doi.org/10.1016/j.parkreldis.2023.105884
Shafiei, G., Bazinet, V., Dadar, M., Manera, A. L., Collins, D. L., Dagher, A., Borroni, B., Sanchez-Valle, R., Moreno, F., Laforce, R., Graff, C., Synofzik, M., Galimberti, D., Rowe, J. B., Masellis, M., Tartaglia, M. C., Finger, E., Vandenberghe, R., de Mendonça, A., … Polyakova, M. (2023). Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain, 146(1), 321–336. https://doi.org/10.1093/brain/awac069